SEPTInvestingStart Free

PHAT SCHEDULE 13D/A: SEC filing

Frazier Life Sciences entities and affiliated individuals

Filed with the SEC on · accession 0001231919-26-001523

PHAT filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 2, 2026. Frazier Life Sciences entities and affiliated individuals filed a joint filing agreement under Schedule 13D/A regarding their ownership of Phathom Pharmaceuticals common stock. The stock moved +3.0% by the first close after the filing.

Summary of the filing

Frazier Life Sciences entities and affiliated individuals filed a joint filing agreement under Schedule 13D/A regarding their ownership of Phathom Pharmaceuticals common stock. The filing is a procedural exhibit establishing that only one statement will be filed on behalf of all reporting persons.

For details, click here →

Key details

Issuer of securitiesPhathom Pharmaceuticals, Inc.
Reporting person / holderFrazier Life Sciences Public Fund, L.P.
General partner of reporting personFHMLSP, L.P.
General partner of fhmlsp, l.p.FHMLSP, L.L.C.
Reporting person / holderFrazier Life Sciences IX, L.P.
General partner of reporting personFHMLS IX, L.P.
General partner of fhmls ix, l.p.FHMLS IX, L.L.C.
Reporting person / holderFrazier Life Sciences X, L.P.
General partner of reporting personFHMLS X, L.P.
General partner of fhmls x, l.p.FHMLS X, L.L.C.
Reporting person / holderFrazier Life Sciences XI, L.P.
General partner of reporting personFHMLS XI, L.P.
General partner of fhmls xi, l.p.FHMLS XI, L.L.C.
Reporting person / holderFrazier Life Sciences XII, L.P.
General partner of reporting personFHMLS XII, L.P.
General partner of fhmls xii, l.p.FHMLS XII, L.L.C.
Chief financial officer, fhmlsp, l.l.c.Jennifer Martin
Reporting personJames N. Topper
Reporting personPatrick J. Heron

How PHAT stock reacted

Close before

$5.74

Oct 30, 2026

First close after

+3.05%

$5.92

5 trading days

-8.54%

$5.25

Since filing

-8.54%

$5.25

✦ Ask GOAX AI about this filing — what it means for PHAT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for PHAT?

Click here

Frequently asked questions

What did PHAT file with the SEC on Nov 2, 2026?

PHAT filed a SCHEDULE 13D/A (SEC filing). Frazier Life Sciences entities and affiliated individuals filed a joint filing agreement under Schedule 13D/A regarding their ownership of Phathom Pharmaceuticals common stock. The filing is a procedural exhibit establishing that only one statement will be filed on behalf of all reporting persons.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did PHAT stock react to this filing?

PHAT closed at $5.74 before the filing and $5.92 on Nov 2, 2026 (+3.05%). Five trading days later: $5.25 (-8.54%).

Other PHAT SEC filings

Get alerts when PHAT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
PHAT overviewPHAT analysisPHAT newsLatest SEC filings